AstraZeneca plans $1.5 billion ADCs manufacturing facility in Singapore
Operationally ready by 2029, it will be the Company’s first-ever facility to cover the full manufacturing process for ADCs
Operationally ready by 2029, it will be the Company’s first-ever facility to cover the full manufacturing process for ADCs
The CRDMO site will add 120,000L manufacturing capacity to WuXi Biologics’ global network
Subscribe To Our Newsletter & Stay Updated